B of A Securities Reiterates Buy on Guardian Pharmacy Services, Inc.
B of A Securities maintained its buy rating for Guardian Pharmacy Services with a $47 price target, a 12.20% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on Guardian Pharmacy Services, Inc. (GRDN) with a price target of $47 on June 17, 2026.
- B of A Securities's $47 price target implies 12.20% upside from Guardian Pharmacy Services, Inc.'s ($GRDN) current $41.89 share price.
- Guardian Pharmacy Services, Inc. trades at $42.42 on the NYSE, with a market cap of about $2.75 billion and a P/E ratio of 51.67.
- Other analysts, including Truist Securities, have maintained buy ratings, with price targets ranging from $38 to $47.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, B of A Securities reiterated its buy rating for Guardian Pharmacy Services, Inc. (NYSE: GRDN), setting a price target of $47. This reflects continued confidence in the company's stock, which recently traded at $42.42.
Analysts Set New Price Targets
B of A Securities maintained its buy rating for Guardian Pharmacy Services with a $47 price target on June 17, 2026. Truist Securities also reiterated their buy recommendation on the same day with a similar target. Earlier, Oppenheimer maintained a buy rating with a $43 target on May 7, 2026. Analysts largely agree on the stock's potential, with a consensus price target averaging $44.17 and a strong buy recommendation across six analyst opinions.
Other Institutional Activity in Guardian Pharmacy Services
Driehaus Capital Management LLC grew its holdings by 82,646 shares, ending with 589,121 shares worth about $22.19 million. Meanwhile, Silvercrest Asset Management Group LLC reduced its holdings by 397,635 shares, now holding 374,946 shares valued at $14.12 million. Peregrine Capital Management LLC also trimmed its position by 19,453 shares, maintaining 201,603 shares worth approximately $7.59 million. Legato Capital Management LLC initiated a new position with 58,890 shares valued at around $2.22 million.
Guardian Pharmacy Services, Inc. Stock Up 13.0%
Shares of Guardian Pharmacy Services, Inc. (NYSE: GRDN) traded near $42.42. The company has a market cap of approximately $2.75 billion and a P/E ratio of 51.67. The stock's 52-week range is between $19.30 and $43.96, with a 50-day moving average of $38.44 and a 200-day moving average of $32.27. The company's current ratio stands at 1.47, quick ratio at 1.1, and a debt-to-equity ratio of 17.72.
Recent Earnings
Guardian Pharmacy Services reported revenue of about $1.46 billion with a modest growth rate of 2.2%. The company's net margin is 3.65%, and it achieved a return on equity of 26.91%. Earnings per share stood at $0.84. The next earnings announcement is scheduled for August 10, 2026.
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc. operates in the healthcare sector, focusing on medical care facilities. Based in Atlanta, Georgia, and led by CEO Mr. Fred P. Burke, the company provides pharmacy services to long-term care facilities across the United States. Guardian Pharmacy supports assisted living, behavioral health facilities, and group homes with its technology-enabled services, including drug dispensing and administration solutions. Founded in 2003, it employs around 3,600 people.
Bottom Line
Guardian Pharmacy Services, Inc. continues to attract positive attention from analysts, with B of A Securities reiterating a buy rating. The company's stock, trading at $42.42, reflects strong market interest, supported by a solid market cap and growth indicators. Investors keep a close watch on such ratings as a part of evaluating potential investments, though 13F filings and analyst ratings are inherently backward-looking and may not reflect current market conditions.
Get Guardian Pharmacy Services, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.